Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies - Xie - iMeta - Wiley Online Library

Targeting the gut microbiota for cancer therapy

Four challenges to CAR T cells breaking the glass ceiling - Bailey - 2023 - European Journal of Immunology - Wiley Online Library

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. - Abstract - Europe PMC

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Cancers, Free Full-Text

Gut microbiome and CAR-T therapy, Experimental Hematology & Oncology

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies - Xie - iMeta - Wiley Online Library

Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions, Biomarker Research

Toxicity and management in CAR T-cell therapy: Molecular Therapy - Oncolytics

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Frontiers Broadening the horizon: potential applications of CAR-T cells beyond current indications